373 related articles for article (PubMed ID: 29865875)
1. The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn's disease.
Lopetuso LR; Napoli M; Rizzatti G; Gasbarrini A
Expert Opin Investig Drugs; 2018 Jun; 27(6):543-551. PubMed ID: 29865875
[TBL] [Abstract][Full Text] [Related]
2. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.
Ponziani FR; Pecere S; Lopetuso L; Scaldaferri F; Cammarota G; Gasbarrini A
Expert Opin Drug Saf; 2016 Jul; 15(7):983-91. PubMed ID: 27149541
[TBL] [Abstract][Full Text] [Related]
3. Role of Rifaximin in Inflammatory Bowel Disease Treatment.
Scribano ML
Mini Rev Med Chem; 2015; 16(3):225-9. PubMed ID: 26202194
[TBL] [Abstract][Full Text] [Related]
4. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases.
Sartor RB
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():27-36. PubMed ID: 26618923
[TBL] [Abstract][Full Text] [Related]
5. The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin.
Ponziani FR; Scaldaferri F; Petito V; Paroni Sterbini F; Pecere S; Lopetuso LR; Palladini A; Gerardi V; Masucci L; Pompili M; Cammarota G; Sanguinetti M; Gasbarrini A
Dig Dis; 2016; 34(3):269-78. PubMed ID: 27027301
[TBL] [Abstract][Full Text] [Related]
6. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease.
Prantera C; Lochs H; Grimaldi M; Danese S; Scribano ML; Gionchetti P;
Gastroenterology; 2012 Mar; 142(3):473-481.e4. PubMed ID: 22155172
[TBL] [Abstract][Full Text] [Related]
7. Rifaximin in the treatment of inflammatory bowel disease.
Guslandi M
World J Gastroenterol; 2011 Nov; 17(42):4643-6. PubMed ID: 22180705
[TBL] [Abstract][Full Text] [Related]
8. Role of antibiotics for treatment of inflammatory bowel disease.
Nitzan O; Elias M; Peretz A; Saliba W
World J Gastroenterol; 2016 Jan; 22(3):1078-87. PubMed ID: 26811648
[TBL] [Abstract][Full Text] [Related]
9. Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system.
Maccaferri S; Vitali B; Klinder A; Kolida S; Ndagijimana M; Laghi L; Calanni F; Brigidi P; Gibson GR; Costabile A
J Antimicrob Chemother; 2010 Dec; 65(12):2556-65. PubMed ID: 20852272
[TBL] [Abstract][Full Text] [Related]
10. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.
Ponziani FR; Gerardi V; Pecere S; D'Aversa F; Lopetuso L; Zocco MA; Pompili M; Gasbarrini A
World J Gastroenterol; 2015 Nov; 21(43):12322-33. PubMed ID: 26604640
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome.
Bruzzese E; Pesce M; Sarnelli G; Guarino A
Expert Opin Drug Metab Toxicol; 2018 Jul; 14(7):753-760. PubMed ID: 29897844
[TBL] [Abstract][Full Text] [Related]
12. Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.
DuPont HL
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():1-2. PubMed ID: 26618920
[TBL] [Abstract][Full Text] [Related]
13. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation.
Ponziani FR; Zocco MA; D'Aversa F; Pompili M; Gasbarrini A
World J Gastroenterol; 2017 Jul; 23(25):4491-4499. PubMed ID: 28740337
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota.
Jin Y; Ren X; Li G; Li Y; Zhang L; Wang H; Qian W; Hou X
J Gastroenterol Hepatol; 2018 Feb; 33(2):443-452. PubMed ID: 28573746
[TBL] [Abstract][Full Text] [Related]
15. Rifaximin: a nonabsorbed oral antibiotic.
Baker DE
Rev Gastroenterol Disord; 2005; 5(1):19-30. PubMed ID: 15741929
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin and Crohn's disease: a new solution to an old problem?
Day AS; Gearry RB
Dig Dis Sci; 2010 Apr; 55(4):877-9. PubMed ID: 20155320
[No Abstract] [Full Text] [Related]
17. Rifaximin, gut microbes and mucosal inflammation: unraveling a complex relationship.
Gao J; Gillilland MG; Owyang C
Gut Microbes; 2014 Jul; 5(4):571-5. PubMed ID: 25244596
[TBL] [Abstract][Full Text] [Related]
18. Rifaximin in the treatment of irritable bowel syndrome: is there a high risk for development of antimicrobial resistance?
Farrell DJ
J Clin Gastroenterol; 2013 Mar; 47(3):205-11. PubMed ID: 23340064
[TBL] [Abstract][Full Text] [Related]
19. Review article: the antimicrobial effects of rifaximin on the gut microbiota.
DuPont HL
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():3-10. PubMed ID: 26618921
[TBL] [Abstract][Full Text] [Related]
20. Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2-Glucose Breath Test.
Biancone L; Vernia P; Agostini D; Ferrieri A; Pallone F
Curr Med Res Opin; 2000; 16(1):14-20. PubMed ID: 16422030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
